SCL Science recorded a ceiling price at the beginning of trading on the 30th.
As of 9:15 a.m. on that day, SCL Science reached a ceiling price of 10,380 won, rising 2,390 won (29.91%) compared to the previous transaction.
SCL Science noted that the health insurance reimbursement for its hemostatic product "Inoseal Plus DL" was confirmed on that day. While the existing product "Inoseal" was a Class 2 product for external use, this product has expanded its applicability to internal use. It creates a rapid hemostatic barrier by reacting with proteins within the body, effectively stopping bleeding.
The price is set at a level 10 times higher than existing external-use products. SCL Science expects this high-value product will help improve future revenue and profitability.